Agios Pharm Valuation
| AGIO Stock | USD 39.92 0.08 0.20% |
At this time, the firm appears to be overvalued. Agios Pharm shows a prevailing Real Value of $36.88 per share. The current price of the firm is $39.92. Our model approximates the value of Agios Pharm from analyzing the firm fundamentals such as Profit Margin of 17.98 %, return on equity of 0.6, and Current Valuation of 1.48 B as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Agios Pharm's price fluctuation is very steady at this time. Calculation of the real value of Agios Pharm is based on 3 months time horizon. Increasing Agios Pharm's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Agios Pharm is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Agios Stock. However, Agios Pharm's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 39.92 | Real 36.88 | Hype 39.92 | Naive 43.01 |
The intrinsic value of Agios Pharm's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Agios Pharm's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Agios Pharm helps investors to forecast how Agios stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Agios Pharm more accurately as focusing exclusively on Agios Pharm's fundamentals will not take into account other important factors: Agios Pharm Total Value Analysis
Agios Pharm is presently forecasted to have valuation of 1.48 B with market capitalization of 2.32 B, debt of 56.99 M, and cash on hands of 819.31 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Agios Pharm fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
1.48 B | 2.32 B | 56.99 M | 819.31 M |
Agios Pharm Investor Information
About 98.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.58. Some equities with similar Price to Book (P/B) outperform the market in the long run. Agios Pharm recorded earning per share (EPS) of 11.54. The entity had not issued any dividends in recent years. Agios Pharm is not in a good financial situation at this time. It has a very high odds of going through financial crisis in August.Agios Pharm Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Agios Pharm has an asset utilization ratio of 2.19 percent. This suggests that the Company is making $0.0219 for each dollar of assets. An increasing asset utilization means that Agios Pharm is more efficient with each dollar of assets it utilizes for everyday operations.Agios Pharm Ownership Allocation
The majority of Agios Pharm outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Agios Pharm to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Agios Pharm. Please pay attention to any change in the institutional holdings of Agios Pharm as this could imply that something significant has changed or is about to change at the company. On May 7, 2025, Representative Gilbert Cisneros of US Congress acquired under $15k worth of Agios Pharm's common stock.Agios Pharm Profitability Analysis
The company reported the previous year's revenue of 36.5 M. Net Income was 673.73 M with loss before overhead, payroll, taxes, and interest of (273 M).About Agios Pharm Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Agios Pharm. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Agios Pharm based exclusively on its fundamental and basic technical indicators. By analyzing Agios Pharm's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Agios Pharm's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Agios Pharm. We calculate exposure to Agios Pharm's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Agios Pharm's related companies.Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. Agios Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 0 people.
Agios Pharm Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 57.9 M | |
| Forward Price Earnings | 2.4655 |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Agios Pharm. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Agios Stock, please use our How to Invest in Agios Pharm guide.You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Agios Pharm. If investors know Agios will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Agios Pharm listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Agios Pharm is measured differently than its book value, which is the value of Agios that is recorded on the company's balance sheet. Investors also form their own opinion of Agios Pharm's value that differs from its market value or its book value, called intrinsic value, which is Agios Pharm's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Agios Pharm's market value can be influenced by many factors that don't directly affect Agios Pharm's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Agios Pharm's value and its price as these two are different measures arrived at by different means. Investors typically determine if Agios Pharm is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Agios Pharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.